Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3Carcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Prostatic Neoplasms 1Primary Myelofibrosis 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 24Cisplatin 24durvalumab 13pembrolizumab 9Oxaliplatin 7Capecitabine 7Fluorouracil 6Leucovorin 5Bevacizumab 5lenvatinib 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Nivolumab 3Liquid Biopsy 3Injections 3Folfox protocol 3Carboplatin 3zanidatamab 2trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2ivosidenib 2futibatinib 2apatinib 2Trastuzumab 2Taxes 2Irinotecan 2Immune Checkpoint Inhibitors 2Drug Therapy 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Biliary Tract Neoplasms × poly ICLC × Clear all
NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡